Movement Alert｜BEONE MEDICINES Falls 3.07% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement Impact

Market Focus09-08 10:18

On September 8, BEONE MEDICINES fell 3.07% in regular trading, trading at HK$208.4/share, with turnover of HK$161 million, extending its multi-day pullback as the market continues to digest the implications of the company's recently announced US Medicaid drug pricing agreement.

On September 1, BEONE MEDICINES announced a voluntary agreement with the US government to supply tislelizumab (Tevimbra) through the Medicaid program at negotiated prices for eligible patients, expected to cover approximately 8% of the drug's approved indication patient population in the US. While multiple brokerages have noted that the pricing framework for core hematology products such as zanubrutinib (Brukinsa) and sonrotoclax remains unaffected, and have maintained buy ratings citing limited near-term financial impact and potential for volume expansion, broader market concerns over US drug pricing policy continue to weigh on sentiment.

Within the Biotechnology sector, overall performance was subdued. Among peers, AKESO fell 0.26%, INNOVENT BIO fell 1.38%, EVEREST MED fell 0.96%, METIS TECHBIO-P rose 9.28%, and DUALITYBIO was flat at 0.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142461319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142461319","market":"us","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Falls 3.07% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement Impact","media":"Market Focus","content":"<p><p>On September 8, BEONE MEDICINES fell 3.07% in regular trading, trading at HK$208.4/share, with turnover of HK$161 million, extending its multi-day pullback as the market continues to digest the implications of the company's recently announced US Medicaid drug pricing agreement.</p><p>On September 1, BEONE MEDICINES announced a voluntary agreement with the US government to supply tislelizumab (Tevimbra) through the Medicaid program at negotiated prices for eligible patients, expected to cover approximately 8% of the drug's approved indication patient population in the US. While multiple brokerages have noted that the pricing framework for core hematology products such as zanubrutinib (Brukinsa) and sonrotoclax remains unaffected, and have maintained buy ratings citing limited near-term financial impact and potential for volume expansion, broader market concerns over US drug pricing policy continue to weigh on sentiment.</p><p>Within the Biotechnology sector, overall performance was subdued. Among peers, AKESO fell 0.26%, INNOVENT BIO fell 1.38%, EVEREST MED fell 0.96%, METIS TECHBIO-P rose 9.28%, and DUALITYBIO was flat at 0.06%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Falls 3.07% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement Impact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Falls 3.07% in Regular Trading, Market Still Digesting US Medicaid Drug Pricing Agreement Impact\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-08 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 8, BEONE MEDICINES fell 3.07% in regular trading, trading at HK$208.4/share, with turnover of HK$161 million, extending its multi-day pullback as the market continues to digest the implications of the company's recently announced US Medicaid drug pricing agreement.</p><p>On September 1, BEONE MEDICINES announced a voluntary agreement with the US government to supply tislelizumab (Tevimbra) through the Medicaid program at negotiated prices for eligible patients, expected to cover approximately 8% of the drug's approved indication patient population in the US. While multiple brokerages have noted that the pricing framework for core hematology products such as zanubrutinib (Brukinsa) and sonrotoclax remains unaffected, and have maintained buy ratings citing limited near-term financial impact and potential for volume expansion, broader market concerns over US drug pricing policy continue to weigh on sentiment.</p><p>Within the Biotechnology sector, overall performance was subdued. Among peers, AKESO fell 0.26%, INNOVENT BIO fell 1.38%, EVEREST MED fell 0.96%, METIS TECHBIO-P rose 9.28%, and DUALITYBIO was flat at 0.06%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1142461319","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142461319","pubTimestamp":1788833885,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 8, BEONE MEDICINES fell 3.07% in regular trading, trading at HK$208.4/share, with turnover of HK$161 million, extending its multi-day pullback as the market continues to digest the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势提醒|BEONE MEDICINES常规交易下跌3.07%，市场仍在消化美国医疗补助药品定价协议的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On September 8, BEONE MEDICINES fell 3.07% in regular trading, trading at HK$208.4/share, with turnover of HK$161 million, extending its multi-day pullback as the market continues to digest the implications of the company's recently announced US Medicaid drug pricing agreement.On September 1, BEONE MEDICINES announced a voluntary agreement with the US government to supply tislelizumab (Tevimbra) through the Medicaid program at negotiated prices for eligible patients, expected to cover approximately 8% of the drug's approved indication patient population in the US. While multiple brokerages have noted that the pricing framework for core hematology products such as zanubrutinib (Brukinsa) and sonrotoclax remains unaffected, and have maintained buy ratings citing limited near-term financial impact and potential for volume expansion, broader market concerns over US drug pricing policy continue to weigh on sentiment.Within the Biotechnology sector, overall performance was subdued. Among peers, AKESO fell 0.26%, INNOVENT BIO fell 1.38%, EVEREST MED fell 0.96%, METIS TECHBIO-P rose 9.28%, and DUALITYBIO was flat at 0.06%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142461319","isCrawlerRequest":true}